CN1803129A - Sodium diclofenac mucilage - Google Patents
Sodium diclofenac mucilage Download PDFInfo
- Publication number
- CN1803129A CN1803129A CN 200510006946 CN200510006946A CN1803129A CN 1803129 A CN1803129 A CN 1803129A CN 200510006946 CN200510006946 CN 200510006946 CN 200510006946 A CN200510006946 A CN 200510006946A CN 1803129 A CN1803129 A CN 1803129A
- Authority
- CN
- China
- Prior art keywords
- diclofenac
- sodium
- rubber cement
- mucilage
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides a novel dosage form of diclofenac sodium for analgesic and pain-relieving, wherein a rectal intestine administration mode is employed for preventing stimulations to gastrointestinal tract and accelerate absorption.
Description
Sodium diclofenac mucilage of the present invention belongs to the novel form of this medicine of diclofenac sodium (diclofenac), and administering mode is a rectally.
Diclofenac sodium is called diclofenac, is held up his spirit, it is a kind of antipyretic analgesic commonly used, and use its tablet and two kinds of dosage forms of suppository [to see Chen Xinqian at present clinical usually, Jin Youyu, Tang Guang chief editor: new pharmacology (the 15th edition), the People's Health Publisher, in JIUYUE, 2003,186～187 pages].And behind the diclofenac sodium tablet oral medication, its common adverse reactions is exactly to the gastrointestinal irritation, show as nauseating, vomiting, epigastrium pain discomfort, stomach burn feeling, inappetence, diarrhoea etc., also can bring out or increase the weight of gastrointestinal ulceration, and can cause hemorrhage or perforation.Need behind the fragrant sour sodium sheet oral administration of chlorine simultaneously 1～2 hour blood drug level could peaking and bring into play its ceiling effect again, such as renal colic, biliary colic etc. sharply the analgesia and the rapid antipyretic patient of some high heat request of pain, oral diclofenac sodium tablet is used for analgesia or analgesicly far can not satisfy its emergent treatment requirement concerning some angor for this.In addition, often be subjected to after the diclofenac sodium tablet is oral the destruction of gastric acid and digestive enzyme and gastrointestinal peristalsis speed, gastrointestinal contents what etc. multiple factor affecting, be the process of a complexity therefore in gastral absorption.And all will enter liver through portal vein through the medicine that gastrointestinal absorbs, so some pharmaceutical compositions absorbs the back and enters the effective dose of body circulation and will reduce through gastrointestinal at liver metabolism or the metabolic medicine of intestinal wall, the drug effect reduction also is the liver first-pass effect of medicine.And diclofenac sodium suppository rectally, though reduced liver first-pass effect to gastrointestinal irritation and medicine, but because the depth of anal position is often filled in the absorption of suppository, the internal rectum body-fluid concentration, the suppository mesostroma dissolves all multifactor influences such as disintegration rate (sees that Wang Ruzhi edits: pharmaceutics, the 3rd edition, the People's Health Publisher, in November, 1999,215～216 pages), sometimes drug effect is stable inadequately, after suppository is filled in rectum simultaneously, need fusing, softening, liquefaction, disintegrate, release molten, absorb this slow process, can not satisfy emergent treatment requirements such as its angor or hyperpyrexia equally.
The object of the invention overcome exactly existing dosage form diclofenac sodium tablet and suppository in clinical, use existing more than deficiency.It has not only avoided GI irritation, reduced the liver first-pass effect of medicine, mucilage rectally post-absorption has improved the bioavailability of this medicine rapidly, fully simultaneously, make that the medicine produce effects is fast, curative effect is high, range of application enlarges, and satisfied needs of medical treatment better.
Production technology of the present invention and method: 1, the prescription of sodium diclofenac mucilage: diclofenac sodium fine powder 5g, sodium carboxymethyl cellulose 20～30g, ethyl hydroxybenzoate solution (5%) 4～8ml, distilled water add to 1000ml.2, technology and method: get sodium carboxymethyl cellulose and be dissolved in an amount of hot distilled water (50～60 ℃), get the diclofenac sodium fine powder again and be dissolved in an amount of distilled water, filter the back and add ethyl hydroxybenzoate solution, two kinds of solution are merged, adding distil water fully stirs evenly promptly to total amount 1000ml.Be distributed into two kinds of bottled specifications of 50mg/10ml, 25mg/5ml, standby after the radiation sterilization.
The present invention has following advantage: 1, be not subjected to the destruction of gastrointestinal tract pH value or enzyme and lose activity.2, generally there is not the gastrointestinal untoward reaction.3, avoided liver first-pass effect basically.4, owing to having improved its bioavailability of medicament, so can improve its antipyretic-antalgic curative effect.5, to can not be oral or be reluctant the adult or the pediatric patient of oral medicine, more convenient with this dosage form.6, can be used for the patient who vomits.7, the mucilage rectally is bigger than the dispersion of suppository medicine, absorption is fast and medicine peak value height, and the performance drug effect is rapid.8, need not suppository fusing, softening, liquefaction, disintegrate, release molten, absorb this slow process.9, repeatedly use the worry of no addiction.10, help the community medicine health care service and carry out, be convenient to popularize and popularization.
Claims (2)
1, sodium diclofenac mucilage (another name diclofenac rubber cement, two chlorine go out logical rubber cement, Diclofenac rubber cement, Diclofenac rubber cement, hold up his clever rubber cement) belongs to the novel form of antipyretic analgesic diclofenac sodium (another name diclofenac), and administering mode is a rectally.
2, feature of the present invention: get sodium carboxymethyl cellulose and be dissolved in an amount of hot distilled water, getting the diclofenac sodium fine powder again is dissolved in an amount of distilled water, filter the back and add ethyl hydroxybenzoate solution, two kinds of solution are merged, adding distil water is to a certain amount of, after fully stirring evenly, be distributed into different bottled specifications, the sterilization back is standby.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510006946 CN1803129A (en) | 2005-01-13 | 2005-01-13 | Sodium diclofenac mucilage |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510006946 CN1803129A (en) | 2005-01-13 | 2005-01-13 | Sodium diclofenac mucilage |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1803129A true CN1803129A (en) | 2006-07-19 |
Family
ID=36865368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510006946 Pending CN1803129A (en) | 2005-01-13 | 2005-01-13 | Sodium diclofenac mucilage |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1803129A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101756789B (en) * | 2009-05-22 | 2012-07-25 | 刘加升 | Preferential three-step method of production process for diclofenac sodium mucilage |
-
2005
- 2005-01-13 CN CN 200510006946 patent/CN1803129A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101756789B (en) * | 2009-05-22 | 2012-07-25 | 刘加升 | Preferential three-step method of production process for diclofenac sodium mucilage |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101292969B (en) | Application of butyric acid (butanoic acid) in preparing medicaments for treating anorectal diseases | |
| CA2860231A1 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| CA2731801C (en) | Therapeutic formulations for the treatment of cold and flu-like symptoms | |
| CN101856338A (en) | Potassium citrate slow-releasing pill | |
| CN1803129A (en) | Sodium diclofenac mucilage | |
| Amadio Jr et al. | NSAIDs revisited: selection, monitoring, and safe use | |
| CN102319208A (en) | Suspension composition for treating oral mucositis caused by chemoradiotherapy | |
| WO2008061409A1 (en) | Enteric coated formulation comprising alkaline active agent and its preparation process | |
| RU2003125876A (en) | MEDICINAL COMPOSITION, INCLUDING DICLOFENAC AND ORNOPROSTIL | |
| CN100484541C (en) | Midicinal composition for treating hemorrhoids and preparation method thereof | |
| CN101810572A (en) | Nimesulide suspension and preparation method thereof | |
| CN102198123B (en) | Ibuprofen microenema preparation and preparation method thereof | |
| CN103432596B (en) | Method for researching abirritation mechanism of Chinese herbal medicinal ingredients of Xinhuang tablets | |
| CN101804040A (en) | Ketoprofen slow-release orally disintegrating tablets | |
| CN105168117B (en) | A kind of (S)-ibuprofen micro emulsion gel and preparation method thereof | |
| CN100379422C (en) | Copmosition of popatyltamo and butyl spiro cyclic ketone | |
| CN106265585A (en) | A kind of Zaltoprofen stomach dissolution type pellet tablet and preparation method thereof | |
| CN102648915A (en) | Medicinal composition for treating or preventing neuropathic pain | |
| CN102247330B (en) | Sustained release tablet prepared from raw material of safflower yellow and preparation method thereof | |
| CN202263198U (en) | Complex gastrointestinal capsule containing combination of diclofenac sodium and acetaminophen | |
| JP4993998B2 (en) | Pharmaceutical composition containing ibuprofen | |
| CN105396054A (en) | Suppository for treating moderate pain of cancer and preparation method of suppository | |
| RU2122849C1 (en) | Suppository showing purgative effect | |
| CN101480389A (en) | Compound for treating primary dysmenorrhea | |
| CN103860551A (en) | Pharmaceutical composition containing etodolac and tramadol hydrochloride and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |